Carbiotix has reached an important milestone in the development of its prebiotic

Carbiotix AB (publ) ("Carbiotix") announces today that the company has successfully completed new enzyme development work for its prebiotic ingredient containing AXOS. This marks an important milestone in the commercialisation of Carbiotix prebiotic fiber and will allow the company to accelerate scale-up and regulatory work in 2020.

Kristofer Cook, CEO for Carbiotix, comments

“Developing a new effective enzyme to hydrolize corn bran into an interesting prebiotic fiber ingredient with desirable properties has been the largest hurdle in the commercialization of the AXOS technology to date. This work has now been successfully completed and we are very happy with both the yields we can achieve with our new enzyme and properties of the corn fiber extract ingredient we can produce, thus making our prebiotic ingredient both economically and functionally desirable. We are now in a position where we can accelerate scale-up and regulatory work required to bring our prebiotic to market as an ingredient for food & beverage and supplement products, as well as other applications. Our prebiotic ingredient is very well positioned in the global prebiotics market soon expected to surpass 5 billion Euros, growing at nearly 10% per annum, and regarded as the No.1 nutrition trend of 2020 (1&2).” 
 
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 10 February 2020. 
 
Forward-looking statements  This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.

For further information:
Carbiotix AB
Kristofer Cook, CEO
Tel: 0708-796580
E-mail: kristofer.cook@carbiotix.com

Carbiotix AB (CRBX) (www.carbiotix.com) is a biotechnology company developing Microbiome Modulator Therapeutics that amplify the production of key metabolites for the treatment of different metabolic and chronic diseases. The company’s therapeutics are based on a propriety AXOS soluble fiber, isolated bacterial strains, and innovative formulations, supported by cost effective gut health testing services used to regularly diagnose and monitor gut health, as well as dose therapeutics.